Trials / Not Yet Recruiting
Not Yet RecruitingNCT05162326
BC-101 in Treatment of Nasolabial Fold Wrinkles
A Phase 1/2 Study of the Safety and Efficacy of BC-101 in Treatment of Nasolabial Fold Wrinkles Via Subcutaneous/Intradermal Injection
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Bright Cell, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm, dose-escalating study to evaluate the safety and tolerability of BC-101 administered via subcutaneous/intradermal injection in the treatment of moderate to severe nasolabial folds.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BC-101 | Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL. |
Timeline
- Start date
- 2026-12-01
- Primary completion
- 2027-12-30
- Completion
- 2028-02-20
- First posted
- 2021-12-17
- Last updated
- 2025-12-29
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05162326. Inclusion in this directory is not an endorsement.